-
Awards
Polyneuron supported by BaseLaunch AcceleratorAfter a first grant of CHF 10’000 during Phase I of the competitive life sciences accelerator initiative, Polyneuron is now supported during Phase II with ready-to-use laboratory and office space, worth CHF 120’000, at the Switzerland Innovation Park Basel Area. [read on]
-
Awards
Polyneuron participates in BaseLaunch AcceleratorPolyneuron was selected into phase I of the new BaseLaunch Accelerator-program. “BaseLaunch aims to support the best healthcare innovators and offers them fast access to founder-friendly venture grants, insights, industry access and state-of-the-art infrastructure. We want to enable and individually guide them to become fully… [read on]
-
General
EMA Orphan Drug Designation for PN-1007Polyneuron has obtained the orphan drug designation from the European Medicines Agency (EMA) for PN-1007 as a novel treatment for anti-MAG neuropathy. The EMA offers a range of incentives with the orphan designation, including free protocol assistance for SMEs, centralized authorization procedure, and extended market… [read on]
-
General
PN-1007 article published in PNASPolyneuron publishes top PN-1007 in vivo data in the renowned scientific journal “PNAS”. Article… [read on]
-
Awards
CTI Start-up LabelPolyneuron is proud to announce that it has obtained the CTI Start-up Label from the Swiss Commission for Technology and Innovation (CTI). The Label is a recognized seal of quality, achievement, credibility, and readiness for sustainable business growth. [read on]
-
Awards
Top5 Swiss Biotech StartupPolyneuron is listed Top5 among the best Swiss Biotech Startups and Top22 among the best 100 Startups in Switzerland. [read on]
-
Awards
Brain Forum Innovation AwardPolyneuron got selected out of more than 120 European neuroscience start-ups and wins the Jury Innovation Award at the Brain Forum 2016. Brain Forum 2016 press release… [read on]
-
Financing
Polyneuron completes seed financing roundPolyneuron announced it has completed a seed financing round raising over CHF 3 million with a group of private investors together with early investors such as the EVA Basel and the ZKB. Press_Release_Polyneuron_20160511… [read on]